Role of immunotherapy in Ewing sarcoma
Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second most common bone sarcoma in pediatric patients and young adults. Given the dismal overall outcomes and very intensive therapies used, there is an urgent need to explore and develop alternative treatment modalities i...
Main Authors: | Erin Morales, Michael Olson, Fiorella Iglesias, Saurabh Dahiya, Tim Luetkens, Djordje Atanackovic |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000653.full |
Similar Items
-
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017-05-01) -
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
by: Peter G. Hendrickson, et al.
Published: (2020-01-01) -
Ewing`s Sarcoma
by: Agnieszka Budny, et al.
Published: (2017-06-01) -
Ewing Sarcoma
by: Hee Young Ju
Published: (2019-04-01) -
NK cell recognition of Ewing's sarcoma
by: Holmes, Tim Dunstan
Published: (2008)